Loading…
UTI - Pharma & Healthcare Fund
Disclosed for 41 months, Jan 2014 to Jun 2017. This scheme is no longer reporting.
Portfolio value
₹312 Cr
up ₹76 L vs Dec 2016
- Stocks held
- 27
- unchanged
- Top 10 weight
- 73.5%
- of the portfolio in its ten largest
- Cash & debt
UTI - Pharma & Healthcare Fund is an active equity fund in the Sectoral / Thematic category from UTI Mutual Fund. In January 2017 it disclosed 27 stocks worth ₹312 Cr, up ₹76 L from Dec 2016. Its largest positions were Sun Pharmaceutical Industries Limited (20.3%), Lupin Limited (10.7%), Dr. Reddy's Laboratories Limited (10.1%); the ten largest together made up 73.5% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 84.6% of its equity. Cash and debt stood at 1.7%. Compared with Dec 2016 the fund entered 0 new stocks and exited 0.
Against 230 other Sectoral / Thematic funds
Concentration
94%
Top-10 weight is higher than 94% of peers
Breadth
11%
Holds more stocks than 11% of peers
Cash
26%
Holds more cash than 26% of peers
What these mean: concentration · cash
Holdings in January 2017
Download CSVEvery line the fund disclosed, with the change against Dec 2016. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Sun Pharmaceutical Industries Limited | 20.34% | down <0.01 pts | ₹63.5 Cr | up ₹15 L | Held |
| Lupin Limited | 10.69% | down 0.14 pts | ₹33.4 Cr | down ₹37 L | Trimmed |
| Dr. Reddy's Laboratories Limited | 10.12% | down 0.16 pts | ₹31.6 Cr | down ₹44 L | Trimmed |
| Cipla Limited | 9.99% | up 0.09 pts | ₹31.2 Cr | up ₹36 L | Added |
| Aurobindo Pharma Limited | 5.86% | up 0.09 pts | ₹18.3 Cr | up ₹34 L | Added |
| Piramal Enterprises Limited | 4.01% | up 0.14 pts | ₹12.5 Cr | up ₹47 L | Added |
| Alkem Laboratories Limited | 3.93% | up 0.08 pts | ₹12.3 Cr | up ₹29 L | Added |
| Divi's Laboratories Limited | 2.91% | down 0.36 pts | ₹9.1 Cr | down ₹1.1 Cr | Trimmed |
| Laurus Labs Limited | 2.81% | down 0.04 pts | ₹8.8 Cr | down ₹11 L | Trimmed |
| Biocon Limited | 2.79% | up 0.16 pts | ₹8.7 Cr | up ₹53 L | Added |
| Narayana Hrudayalaya Limited | 2.74% | down 0.03 pts | ₹8.6 Cr | down ₹8 L | Trimmed |
| IPCA Laboratories Limited | 2.51% | up <0.01 pts | ₹7.8 Cr | up ₹3 L | Held |
| Zydus Lifesciences Limited | 2.41% | down 0.05 pts | ₹7.5 Cr | down ₹13 L | Trimmed |
| Sun Pharma Advanced Research Company Limited | 2.37% | down 0.01 pts | ₹7.4 Cr | down ₹1 L | Held |
| Syngene International Limited | 2.22% | down 0.07 pts | ₹6.9 Cr | down ₹20 L | Trimmed |
| Strides Pharma Science Limited | 2.14% | up 0.24 pts | ₹6.7 Cr | up ₹77 L | Added |
| Cash, TREPS & receivables | 1.74% | up 0.31 pts | ₹5.4 Cr | up ₹99 L | Added |
| Pfizer Limited | 1.65% | down 0.04 pts | ₹5.2 Cr | down ₹13 L | Trimmed |
| Unichem Laboratories Limited | 1.51% | up 0.08 pts | ₹4.7 Cr | up ₹25 L | Added |
| Natco Pharma Limited | 1.34% | up 0.21 pts | ₹4.2 Cr | up ₹68 L | Added |
| GlaxoSmithKline Pharmaceuticals Limited | 1.11% | down 0.01 pts | ₹3.5 Cr | down ₹1 L | Held |
| Indraprastha Medical Corporation Limited | 1.10% | up 0.06 pts | ₹3.4 Cr | up ₹20 L | Added |
| Sanofi India Limited | 1.00% | down 0.62 pts | ₹3.1 Cr | down ₹1.9 Cr | Trimmed |
| DISHMAN PHARMACEUTICALS & CHEMICALS LTD. | 0.88% | up 0.04 pts | ₹2.7 Cr | up ₹12 L | Added |
| Shilpa Medicare Limited | 0.67% | up 0.01 pts | ₹2.1 Cr | up ₹4 L | Added |
| Torrent Pharmaceuticals Limited | 0.59% | down 0.01 pts | ₹1.9 Cr | down ₹2 L | Trimmed |
| Indoco Remedies Limited | 0.38% | up 0.01 pts | ₹1.2 Cr | up ₹3 L | Added |
| Thyrocare Technologies Limited | 0.17% | up <0.01 pts | ₹52 L | up ₹1 L | Added |
What changed, Dec 2016 to Jan 2017
New New positions (0)
None.
Exited Exited (0)
None.
Added Biggest additions
- Strides Pharma Science Limitedup ₹77 L (+0.24% pts)
- Natco Pharma Limitedup ₹68 L (+0.21% pts)
- Biocon Limitedup ₹53 L (+0.16% pts)
- Piramal Enterprises Limitedup ₹47 L (+0.14% pts)
- Cipla Limitedup ₹36 L (+0.09% pts)
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Dec 2016, the weight rose most in Pharmaceuticals (+0.4 pts) and Finance (+0.2 pts), and fell most in Pharmaceuticals & Biotechnology (−0.5 pts).
- Pharmaceuticals4.6% → 5.0%+0.4 pts
- Finance3.9% → 4.1%+0.2 pts
- Pharmaceuticals & Biotechnology85.1% → 84.6%−0.5 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Jan 2014 | Jan 2016 | Jul 2016 | Oct 2016 | Dec 2016 | Jan 2017 |
|---|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 91.6% | 86.7% | 86.6% | 85.1% | 85.1% | 84.6% |
| Healthcare Services | — | 5.5% | 5.1% | 6.2% | 6.4% | 6.3% |
| Pharmaceuticals | 7.3% | 4.8% | 4.6% | 4.6% | 4.6% | 5.0% |
| Finance | 1.1% | 3.0% | 3.7% | 4.0% | 3.9% | 4.1% |
Allocation in Jan 2017change vs Dec 2016
- Pharmaceuticals & Biotechnology (18)84.6%▼ 0.5 pts
- Healthcare Services (4)6.3%
- Pharmaceuticals (4)5.0%▲ 0.4 pts
- Finance (1)
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, Jan 2017
1.7%
▲ 0.3 pts vs Dec 2016
- Cash alone
- 1.7%
- cash and net receivables
- A year earlier
- 9.4%
- Jan 2016 · now ▼ 7.6 pts
- Last 12 months
- 0.7% – 11.7%
- lowest to highest · record 12.6% in Nov 2015
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.